HK1204549A1 - A tuberculosis tb vaccine to prevent reactivation tb - Google Patents

A tuberculosis tb vaccine to prevent reactivation tb

Info

Publication number
HK1204549A1
HK1204549A1 HK15103708.0A HK15103708A HK1204549A1 HK 1204549 A1 HK1204549 A1 HK 1204549A1 HK 15103708 A HK15103708 A HK 15103708A HK 1204549 A1 HK1204549 A1 HK 1204549A1
Authority
HK
Hong Kong
Prior art keywords
tuberculosis
vaccine
prevent reactivation
reactivation
prevent
Prior art date
Application number
HK15103708.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧迪特裡希
彼得‧安德森
卡裡納‧溫斯波‧倫德貝裡
特呂克‧蒂‧吉姆‧坦‧候昂
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of HK1204549A1 publication Critical patent/HK1204549A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15103708.0A 2009-04-24 2012-07-11 A tuberculosis tb vaccine to prevent reactivation tb HK1204549A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24

Publications (1)

Publication Number Publication Date
HK1204549A1 true HK1204549A1 (en) 2015-11-27

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15103708.0A HK1204549A1 (en) 2009-04-24 2012-07-11 A tuberculosis tb vaccine to prevent reactivation tb
HK12106837.0A HK1166018A1 (zh) 2009-04-24 2012-07-11 預防再激活的結核病 疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12106837.0A HK1166018A1 (zh) 2009-04-24 2012-07-11 預防再激活的結核病 疫苗

Country Status (17)

Country Link
US (2) US9074001B2 (xx)
EP (1) EP2421557B1 (xx)
JP (2) JP5839361B2 (xx)
KR (2) KR20120014176A (xx)
CN (2) CN104107425B (xx)
AU (1) AU2010238943B9 (xx)
BR (1) BRPI1006452A2 (xx)
CA (1) CA2759583C (xx)
DK (1) DK2421557T3 (xx)
ES (1) ES2714383T3 (xx)
HK (2) HK1204549A1 (xx)
IL (1) IL215591A (xx)
MX (2) MX370744B (xx)
PL (1) PL2421557T3 (xx)
TR (1) TR201903223T4 (xx)
WO (1) WO2010121618A1 (xx)
ZA (1) ZA201108564B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
NO2315597T3 (xx) 2008-07-25 2018-01-20
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
HUE039159T2 (hu) 2008-07-25 2018-12-28 Glaxosmithkline Biologicals Sa Tuberkulózis Rv2386c protein, ezt tartalmazó készítmények és ezek alkalmazása
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
MX2012008790A (es) 2010-01-27 2012-08-17 Glaxosmithkline Biolog Sa Antigenos de tuberculosis modificados.
RU2648842C2 (ru) * 2011-01-04 2018-03-28 Арчивель Фарма, С.Л. Липосомный препарат, предназначенный для лечения или предупреждения туберкулеза
RU2602771C2 (ru) 2012-01-12 2016-11-20 Арчивель Фарма, С.Л. Вакцина мбтк против астмы
BR112015009070A2 (pt) * 2012-10-23 2017-07-04 Statens Seruminstitut proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
EP2968496A4 (en) 2013-03-15 2016-07-27 Univ Pennsylvania SYNTHESIS IMMUNOGENS FOR PROPHYLAXIS OR TREATMENT OF TUBERCULOSIS
US10641770B2 (en) * 2013-12-16 2020-05-05 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
US10765731B2 (en) * 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EP3134116B1 (en) * 2014-04-24 2019-04-03 Statens Serum Institut New m.tuberculosis vaccines
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
MX2018014270A (es) * 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
MX2020011298A (es) * 2018-04-26 2021-01-29 Childrens Nat Medical Ct Composiciones de antígeno micobacteriano y métodos de uso.
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
AU721954B2 (en) 1995-06-07 2000-07-20 Connaught Laboratories Inc. Expression of lipoproteins
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
AU779495B2 (en) 1999-07-13 2005-01-27 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family
EP1278769A2 (en) 2000-04-19 2003-01-29 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
US7135280B2 (en) * 2001-01-08 2006-11-14 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
DE60236573D1 (de) * 2002-04-05 2010-07-15 Pasteur Institut Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht
AU2003242504A1 (en) 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
US7678379B2 (en) * 2004-06-17 2010-03-16 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
KR101255870B1 (ko) * 2004-11-16 2013-04-17 아에라스 글로벌 티비 백신 파운데이션 재조합 바이러스 벡터를 포함하는 다가 백신
CA2592756A1 (en) * 2005-01-05 2006-07-13 Isis Innovation Limited Compositions for immunizing against mycobacterium
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
EP1910409A2 (en) * 2005-06-23 2008-04-16 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP2402024A1 (en) * 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods

Also Published As

Publication number Publication date
IL215591A0 (en) 2011-12-29
AU2010238943A1 (en) 2011-11-03
EP2421557B1 (en) 2018-12-05
AU2010238943A9 (en) 2015-10-15
MX370744B (es) 2019-12-20
CN104107425B (zh) 2018-07-17
KR20120014176A (ko) 2012-02-16
JP2012524733A (ja) 2012-10-18
US9074001B2 (en) 2015-07-07
KR20170072366A (ko) 2017-06-26
EP2421557A4 (en) 2013-03-13
WO2010121618A1 (en) 2010-10-28
MX2011011186A (es) 2012-02-13
US10519202B2 (en) 2019-12-31
AU2010238943B9 (en) 2015-10-15
HK1166018A1 (zh) 2012-10-19
IL215591A (en) 2016-03-31
AU2010238943B2 (en) 2015-09-17
PL2421557T3 (pl) 2019-07-31
ES2714383T3 (es) 2019-05-28
US20120039925A1 (en) 2012-02-16
EP2421557A1 (en) 2012-02-29
TR201903223T4 (tr) 2019-03-21
JP5839361B2 (ja) 2016-01-06
CA2759583C (en) 2020-06-16
JP6215260B2 (ja) 2017-10-18
CN104107425A (zh) 2014-10-22
DK2421557T3 (en) 2019-03-25
ZA201108564B (en) 2018-11-28
CA2759583A1 (en) 2010-10-28
BRPI1006452A2 (pt) 2016-12-27
US20150093407A1 (en) 2015-04-02
JP2015199771A (ja) 2015-11-12
CN102413837A (zh) 2012-04-11
CN102413837B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
HK1204549A1 (en) A tuberculosis tb vaccine to prevent reactivation tb
IL217008A0 (en) Vaccine
GB0905570D0 (en) Combined vaccines
GB0905234D0 (en) Protien recovery
HK1256627A1 (zh) 作為疫苗的重組分枝桿菌
GB201006165D0 (en) Vaccine
GB201001726D0 (en) Bunyavirus vaccine
GB2491793B (en) A buffer
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB201000522D0 (en) Vaccine
IL217194A0 (en) Vaccine
GB0908326D0 (en) Tuberculosis vaccine
GB0910001D0 (en) TB vaccine
GB2499103B (en) A Pillow
ZA201107971B (en) Combined measles-malaria vaccine
GB2468371B (en) A buffer
GB0914545D0 (en) Vaccine
AU331345S (en) A pillow
IL209643A0 (en) A page-turning system
GB201009553D0 (en) Childrens bed sheets
GB0909145D0 (en) Vaccines
GB0909144D0 (en) Vaccines
GB0909146D0 (en) Vaccines
GB0909147D0 (en) Vaccines